DTI 301
Alternative Names: DTI-301Latest Information Update: 28 Feb 2025
At a glance
- Originator Dignify Therapeutics
- Class Peptides
- Mechanism of Action TRPV cation channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Constipation; Gastrointestinal disorders
Most Recent Events
- 28 Feb 2025 Preclinical trials in Constipation in USA (Rectal) before February 2025 (Dignify Therapeutics pipeline, February 2025)
- 28 Feb 2025 Preclinical trials in Gastrointestinal disorders in USA (Rectal) before February 2025 (Dignify Therapeutics pipeline, February 2025)